WS #13444
Holding: newest synthesis is 97d 19h old
Novo Nordisk raised FY guidance but analysts were unimpressed ('nothing to inspire' - Citi), with oral Wegovy slightly missing forecasts and another mixed CagriSema clinical result, reinforcing competition concerns from Eli Lilly.
Novo Nordisk guidance raise fails to impress
Novo Nordisk raised FY guidance but analysts were unimpressed ('nothing to inspire' - Citi), with oral Wegovy slightly missing forecasts and another mixed CagriSema clinical result, reinforcing competition concerns from Eli Lilly.